Patents by Inventor Edward John Miracco

Edward John Miracco has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Polynucleotides containing a stabilizing tail region
    Patent number: 12109274
    Abstract: The invention features polynucleotides encoding a polypeptide including a 3?-stabilizing region and having increased stability compared to wild-type polynucleotides.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: October 8, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Gabor Butora, Andrew W. Fraley, Edward John Miracco, Jennifer Nelson, Amy Rhoden Smith, Matthew Stanton, Brian R. Fritz
  • Polynucleotides containing a morpholino linker
    Patent number: 12071620
    Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.
    Type: Grant
    Filed: September 6, 2022
    Date of Patent: August 27, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Gabor Butora, Andrew W. Fraley, Edward John Miracco, Jennifer Nelson, Amy Rhoden Smith, Matthew Stanton
  • Trinucleotide mRNA cap analogs
    Patent number: 11866754
    Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
    Type: Grant
    Filed: October 17, 2016
    Date of Patent: January 9, 2024
    Assignee: ModernaTX, Inc.
    Inventors: Gabor Butora, Matthew Stanton, Edward John Miracco
  • ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
    Publication number: 20230416324
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Application
    Filed: October 25, 2022
    Publication date: December 28, 2023
    Inventors: Stephen G. HOGE, William Joseph ISSA, Edward John MIRACCO, Jennifer NELSON, John REYNDERS, Matthew STANTON
  • POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER
    Publication number: 20230323344
    Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.
    Type: Application
    Filed: September 6, 2022
    Publication date: October 12, 2023
    Inventors: Gabor BUTORA, Andrew W. Fraley, Edward John Miracco, Jennifer Nelson, Amy Rhoden Smith, Matthew Stanton
  • Polynucleotides containing a morpholino linker
    Patent number: 11434486
    Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.
    Type: Grant
    Filed: September 19, 2016
    Date of Patent: September 6, 2022
    Assignee: ModernaTX, Inc.
    Inventors: Gabor Butora, Andrew W. Fraley, Edward John Miracco, Jennifer Nelson, Amy Rhoden Smith, Matthew Stanton
  • TRINUCLEOTIDE MRNA CAP ANALOGS
    Publication number: 20190211368
    Abstract: The present disclosure relates to cap analogs, which can result in high levels of capping efficiency and transcription and improved translation efficiencies. The present disclosure also relates to methods useful for preparing cap analogs and using mRNA species containing such analogs, as well as kits containing the novel cap analogs.
    Type: Application
    Filed: October 17, 2016
    Publication date: July 11, 2019
    Inventors: Gabor BUTORA, Matthew STANTON, Edward John MIRACCO
  • ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
    Publication number: 20190092828
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Application
    Filed: July 30, 2018
    Publication date: March 28, 2019
    Inventors: Stephen G. HOGE, William Joseph ISSA, Edward John MIRACCO, Jennifer NELSON, John REYNDERS, Matthew STANTON
  • POLYNUCLEOTIDES CONTAINING A MORPHOLINO LINKER
    Publication number: 20190078087
    Abstract: The disclosure provides polynucleotides encoding a polypeptide including a morpholino linker. In some embodiments, the polynucleotides of the invention have increased stability compared to wild-type polynucleotides.
    Type: Application
    Filed: September 19, 2016
    Publication date: March 14, 2019
    Inventors: Gabor BUTORA, Andrew W. FRALEY, Edward John MIRACCO, Jennifer NELSON, Amy RHODEN-SMITH, Matthew STANTON
  • POLYNUCLEOTIDES CONTAINING A STABILIZING TAIL REGION
    Publication number: 20180256750
    Abstract: The invention features polynucleotides encoding a polypeptide including a 3?-stabilizing region and having increased stability compared to wild-type polynucleotides.
    Type: Application
    Filed: September 19, 2016
    Publication date: September 13, 2018
    Applicant: MODERNA THERAPEUTICS, INC.
    Inventors: Gabor BUTORA, Andrew W. FRALEY, Edward John MIRACCO, Jennifer NELSON, Amy RHODEN-SMITH, Matthew STANTON
  • Alternative nucleic acid molecules containing reduced uracil content and uses thereof
    Patent number: 10072057
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Grant
    Filed: July 21, 2017
    Date of Patent: September 11, 2018
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, William Joseph Issa, Edward John Miracco, Jennifer Nelson, John Reynders, Matthew Stanton
  • ALTERNATIVE NUCLEIC ACID MOLECULES CONTAINING REDUCED URACIL CONTENT AND USES THEREOF
    Publication number: 20180009866
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Application
    Filed: July 21, 2017
    Publication date: January 11, 2018
    Inventors: Stephen G. Hoge, William Joseph Issa, Edward John Miracco, Jennifer Nelson, John Reynders, Matthew Stanton
  • Alternative nucleic acid molecules containing reduced uracil content and uses thereof
    Patent number: 9751925
    Abstract: The present disclosure provides alternative nucleosides, nucleotides, and nucleic acids, and methods of using them. In some aspects, the disclosure provides mRNA wherein the uracil content has been modified and which may be particularly effective for use in therapeutic compositions, because they may benefit from both high expression levels and limited induction of the innate immune response. In some aspects, the disclosure provides methods for the production of pharmaceutical compositions including mRNA without reverse phase chromatography.
    Type: Grant
    Filed: December 4, 2015
    Date of Patent: September 5, 2017
    Assignee: ModernaTX, Inc.
    Inventors: Stephen G. Hoge, William Joseph Issa, Edward John Miracco, Jennifer Nelson, John Reynders, Matthew Stanton